A. Sinclair Dunlop - 01 Feb 2023 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Director
Signature
/s/ David Watson, attorney-in-fact for Sinclair Dunlop
Issuer symbol
APLS
Transactions as of
01 Feb 2023
Net transactions value
-$26,305
Form type
4
Filing time
02 Feb 2023, 15:15:16 UTC
Previous filing
05 Jan 2023
Next filing
02 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Sale $26,305 -500 -0.38% $52.61 132,297 01 Feb 2023 Direct F1
holding APLS Common Stock 240,679 01 Feb 2023 Indirect Owner (Epidarex) F2
holding APLS Common Stock 31,855 01 Feb 2023 Indirect Owner (Masa) F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported on this Form 4 was effected by pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 23, 2022.
F2 The securities are held by Epidarex and the reporting person, a general partner of Epidarex, may be deemed to have voting and dispositive power over the shares held by Epidarex. The reporting person disclaims beneficial ownership over the shares held by Epidarex except to the extent of his pecuniary interest therein.
F3 The securities are held by MASA and the reporting person, a managing partner of MASA, may be deemed to have voting and dispositive power over the shares held by MASA. The reporting person disclaims beneficial ownership over the shares held by MASA except to the extent of his pecuniary interest therein.